Beyond classical benzodiazepines: Novel therapeutic potential of GABAA receptor subtypes
By U. Rudolph, F. Knoflach. Nature reviews. Drug discovery, 2011
722 citations recorded by the source corpus.
GABAA (γ-aminobutyric acid, type A) receptors are a family of ligand-gated ion channels that are essential for the regulation of central nervous system function. Benzodiazepines — which non-selectively target GABAA receptors containing the α1, α2, α3 or α5 subunits — have been in clinical use for decades and are still among the most widely prescribed drugs for the treatment of insomnia and anxiety disorders. However, their use is limited by side effects and the risk of drug dependence. In the past decade, the identification of separable key functions of GABAA receptor subtypes suggests that receptor subtype-selective compounds could overcome the limitations of classical benzodiazepines; furthermore, they might be valuable for novel indications such as chronic pain, depression, schizophrenia, cognitive enhancement and stroke.
Subfields: Cellular and Molecular Neuroscience, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/bfb4fcd647899053b94eaf5edf1fe9e748076c6b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Jiyao Sheng
- R. Cui
- Xuewen Zhang
- Shui Liu
- Yicun Wang
Citations in the corpus
- The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain (2017, background): “Because the GABAA receptors, including the α1, α2, α3, or α5 subunit, have also been found to be involved in mood regulation [82], the benzodiazepines have a potential in antidepressant therapy.”